Potential vaginal probiotics: safety, tolerability and preliminary effectiveness
In: Beneficial MicrobesDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by M. Rostok in
Current site
Google Scholar
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by P. Hütt in
Current site
Google Scholar
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by T. Rööp in
Current site
Google Scholar
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by I. Smidt in
Current site
Google Scholar
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by J. Štšepetova in
Current site
Google Scholar
Search for other papers by A. Salumets in
Current site
Google Scholar
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by R. Mändar in
Current site
Google Scholar
Vaginal discharge is one of the common reasons for gynaecologist consultation, as bacterial vaginosis and candidiasis are the main causes of discharge. These patients frequently experience numerous problems due to recurrent infections, side effects and drug resistance therefore alternative drugs are needed. Our primary aim was to evaluate safety and tolerability of the potentially probiotic Lactobacillus crispatus strains in volunteer women considering themselves healthy. We also monitored the effects of these strains on vaginal health parameters and lactobacilli counts in vagina and intestine. Forty women were recruited into trial. Absence of chronic diseases was confirmed by questionnaire and blood analysis at screening visit. In randomised double-blind placebo-controlled crossover study the eligible participants were randomly allocated to one of four groups and had to consume one of the two study products (Pro I or Pro II) – a capsule containing 3 strains, 109 cfu per strain, or placebo for 1 week. Treatment period was followed by 2-week washout period and continued with second treatment and washout period. Individuals receiving firstly probiotic, received later placebo and vice versa. Blood, vaginal and faecal samples were collected, and self-reported questionnaires were applied. Thirty subjects completed the trial. The probiotic capsules were well-tolerated. The Pro II intake resulted in a significant decrease in Nugent score (from median 3.0 to 2.0, mean 3.9 to 2.6, P=0.002) and reduction in Gardnerella vaginalis counts (log10 3.57 to 2.38; P=0.027). Reduction of total vaginal bacterial counts was revealed in Pro I group (log10 7.99 to 7.72; P=0.048). In conclusion, the selected vaginal L. crispatus strains are well tolerable and Pro II mixture is prospectively effective in reducing Nugent score and vaginal counts of G. vaginalis. Therefore, these strains seem to be promising candidates for development of novel evidence-based well-focused probiotics to target female urogenital tract disorders.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Amabebe, E. and Anumba, D.O.C., 2018. The vaginal microenvironment: the physiologic role of Lactobacilli. Frontiers in Medicine 5: 181.
'The vaginal microenvironment: the physiologic role of Lactobacilli ' () 5 Frontiers in Medicine : 181 .
-
Antonio, M.A. and Hillier, S.L., 2003. DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. Journal of Clinical Microbiology 41: 1881-1887.
'DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization ' () 41 Journal of Clinical Microbiology : 1881 -1887 .
-
Bartosch, S., Fite, A., Macfarlane, G.T. and McMurdo, M.E., 2004. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Applied and Environmental Microbiology 70: 3575-3581.
'Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota ' () 70 Applied and Environmental Microbiology : 3575 -3581 .
-
Borges, S., Silva, J. and Teixeira, P., 2014. The role of lactobacilli and probiotics in maintaining vaginal health. Archives of Gynecology and Obstetrics 289: 479-489.
'The role of lactobacilli and probiotics in maintaining vaginal health ' () 289 Archives of Gynecology and Obstetrics : 479 -489 .
-
Czaja, C.A., Stapleton, A.E., Yarova-Yarovaya, Y. and Stamm, W.E., 2007. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infectious Diseases in Obstetrics and Gynecology 2007: 35387.
'Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women ' () 2007 Infectious Diseases in Obstetrics and Gynecology : 35387 .
-
Fite, A., Macfarlane, G.T., Cummings, J.H., Hopkins, M.J., Kong, S.C., Furrie, E. and Macfarlane, S., 2004. Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction. Gut 53: 523-529.
'Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction ' () 53 Gut : 523 -529 .
-
Foschi, C., Salvo, M., Cevenini, R., Parolin, C., Vitali, B. and Marangoni, A., 2017. Vaginal Lactobacilli reduce Neisseria gonorrhoeae viability through multiple strategies: an in vitro study. Frontiers in Cellular and Infection Microbiology 7: 502.
'Vaginal Lactobacilli reduce Neisseria gonorrhoeae viability through multiple strategies: an in vitro study ' () 7 Frontiers in Cellular and Infection Microbiology : 502 .
-
Hemmerling, A., Harrison, W., Schroeder, A., Park, J., Korn, A., Shiboski, S. and Cohen, C.R., 2009. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 (LACTIN-V) for the prevention of bacterial vaginosis. Sexually Transmitted Diseases 36: 564-569.
'Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 (LACTIN-V) for the prevention of bacterial vaginosis ' () 36 Sexually Transmitted Diseases : 564 -569 .
-
Homayouni, A., Bastani, P., Ziyadi, S., Mohammad-Alizadeh-Charandabi, S., Ghalibaf, M., Mortazavian, A.M. and Mehrabany, E.V., 2014. Effects of probiotics on the recurrence of bacterial vaginosis: a review. Journal of Lower Genital Tract Disease 18: 79-86.
'Effects of probiotics on the recurrence of bacterial vaginosis: a review ' () 18 Journal of Lower Genital Tract Disease : 79 -86 .
-
Hütt, P., Lapp, E., Štšepetova, J., Smidt, I., Taelma, H., Borovkova, N., Oopkaup, H., Ahelik, A., Rööp, T., Hoidmets, D., Samuel, K., Salumets, A. and Mändar, R., 2016. Characterisation of probiotic properties in human vaginal lactobacilli strains. Microbial Ecology in Health and Diseases 27: 30484.
'Characterisation of probiotic properties in human vaginal lactobacilli strains ' () 27 Microbial Ecology in Health and Diseases : 30484 .
-
Macklaim, J.M., Clemente, J.C., Knight, R., Gloor, G.B. and Reid, G., 2015. Changes in vaginal microbiota following antimicrobial and probiotic therapy. Microbial Ecology in Health and Disease 26: 277-299.
'Changes in vaginal microbiota following antimicrobial and probiotic therapy ' () 26 Microbial Ecology in Health and Disease : 277 -299 .
-
Mändar, R., Hütt, P., Smidt, I., Štšepetova, J., Lapp, E., Rostok, M., Sõerunurk, G., Rööp, T., Hoidmets, D., Tamm, H., Kolk, M., Piiskop, S., Palmiste, T., Koort, K. and Salumets, A., 2018. Vaginal Lactobacillus crispatus strains as probiotics for urogenital health. Tervisetehnoloogiate Arenduskeskus AS, assignee. Pat. Appl. No. 1816425.1 09.10.2018.
'Vaginal Lactobacillus crispatus strains as probiotics for urogenital health ', in Tervisetehnoloogiate Arenduskeskus AS, assignee , ().
-
Mastromarino, P., Vitali, B. and Mosca, L., 2013. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiologica 36: 229-238.
'Bacterial vaginosis: a review on clinical trials with probiotics ' () 36 New Microbiologica : 229 -238 .
-
Menard, J.P., Fenollar, F., Henry, M., Bretelle, F. and Raoult, D., 2008. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clinical Infectious Diseases 47: 33-43.
'Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis ' () 47 Clinical Infectious Diseases : 33 -43 .
-
Modak, T., Arora, P., Agnes, C., Ray, R., Goswami, S., Ghosh, P. and Das, N.K., 2011. Diagnosis of bacterial vaginosis in cases of abnormal vaginal discharge: comparison of clinical and microbiological criteria. Journal of Infection in Developing Countries 5: 353-360.
'Diagnosis of bacterial vaginosis in cases of abnormal vaginal discharge: comparison of clinical and microbiological criteria ' () 5 Journal of Infection in Developing Countries : 353 -360 .
-
Nardini, P., Ñahui Palomino, R.A., Parolin, C., Laghi, L., Foschi, C., Cevenini, R., Vitali, B. and Marangoni, A., 2016. Lactobacillus crispatus inhibits the infectivity of Chlamydia trachomatis elementary bodies, in vitro study. Science Reports 6: 29024.
'Lactobacillus crispatus inhibits the infectivity of Chlamydia trachomatis elementary bodies, in vitro study ' () 6 Science Reports : 29024 .
-
Nugent, R.P., Krohn, M.A. and Hillier, S.L., 1991. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. Journal of Clinical Microbiology 29: 297-301.
'Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation ' () 29 Journal of Clinical Microbiology : 297 -301 .
-
Pendharkar, S., Brandsborg, E., Hammarström, L., Marcotte, H. and Larsson, P.G., 2015. Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection. BMC Infectious Diseases 15: 255.
'Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection ' () 15 BMC Infectious Diseases : 255 .
-
Russo, R., Edu, A. and De Seta, F., 2018. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Archives of Gynecology and Obstetrics 298: 139-145.
'Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota ' () 298 Archives of Gynecology and Obstetrics : 139 -145 .
-
Sanders, M.E., 2008. Probiotics: definition, sources, selection, and uses. Clinical Infectious Diseases 46: 144-151.
'Probiotics: definition, sources, selection, and uses ' () 46 Clinical Infectious Diseases : 144 -151 .
-
Shipitsyna, E., Roos, A., Datcu, R., Hallén, A., Fredlund, H., Jensen, J.S., Engstrand, L. and Unemo, M., 2013. Composition of the vaginal microbiota in women of reproductive age – sensitive and specific molecular diagnosis of bacterial vaginosis is possible? PLoS ONE 8: e60670.
'Composition of the vaginal microbiota in women of reproductive age – sensitive and specific molecular diagnosis of bacterial vaginosis is possible? ' () 8 PLoS ONE : e60670 .
-
Sweet, R.L. and Gibbs, R.S., 2009. Infectious disease of female genital tract, 5th edition. Williams and Wilkins, Baltimore, MD, USA.
'Infectious disease of female genital tract, 5th edition ', ().
Supplementary Materials
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 67 | 67 | 36 |
| Full Text Views | 16 | 16 | 1 |
| PDF Views & Downloads | 27 | 27 | 6 |
Potential vaginal probiotics: safety, tolerability and preliminary effectiveness
In: Beneficial MicrobesDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by M. Rostok in
Current site
Google Scholar
PubMed
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by P. Hütt in
Current site
Google Scholar
PubMed
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by T. Rööp in
Current site
Google Scholar
PubMed
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by I. Smidt in
Current site
Google Scholar
PubMed
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by J. Štšepetova in
Current site
Google Scholar
PubMed
Search for other papers by A. Salumets in
Current site
Google Scholar
PubMed
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia.
Search for other papers by R. Mändar in
Current site
Google Scholar
PubMed
Vaginal discharge is one of the common reasons for gynaecologist consultation, as bacterial vaginosis and candidiasis are the main causes of discharge. These patients frequently experience numerous problems due to recurrent infections, side effects and drug resistance therefore alternative drugs are needed. Our primary aim was to evaluate safety and tolerability of the potentially probiotic Lactobacillus crispatus strains in volunteer women considering themselves healthy. We also monitored the effects of these strains on vaginal health parameters and lactobacilli counts in vagina and intestine. Forty women were recruited into trial. Absence of chronic diseases was confirmed by questionnaire and blood analysis at screening visit. In randomised double-blind placebo-controlled crossover study the eligible participants were randomly allocated to one of four groups and had to consume one of the two study products (Pro I or Pro II) – a capsule containing 3 strains, 109 cfu per strain, or placebo for 1 week. Treatment period was followed by 2-week washout period and continued with second treatment and washout period. Individuals receiving firstly probiotic, received later placebo and vice versa. Blood, vaginal and faecal samples were collected, and self-reported questionnaires were applied. Thirty subjects completed the trial. The probiotic capsules were well-tolerated. The Pro II intake resulted in a significant decrease in Nugent score (from median 3.0 to 2.0, mean 3.9 to 2.6, P=0.002) and reduction in Gardnerella vaginalis counts (log10 3.57 to 2.38; P=0.027). Reduction of total vaginal bacterial counts was revealed in Pro I group (log10 7.99 to 7.72; P=0.048). In conclusion, the selected vaginal L. crispatus strains are well tolerable and Pro II mixture is prospectively effective in reducing Nugent score and vaginal counts of G. vaginalis. Therefore, these strains seem to be promising candidates for development of novel evidence-based well-focused probiotics to target female urogenital tract disorders.
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 67 | 67 | 36 |
| Full Text Views | 16 | 16 | 1 |
| PDF Views & Downloads | 27 | 27 | 6 |